--- title: "Lunai Bioworks Inc. SEC 10-Q Report" type: "News" locale: "en" url: "https://longbridge.com/en/news/276164384.md" description: "Lunai Bioworks Inc. has released its latest Form 10-Q report, indicating improved financial performance with total operating expenses down to $5.13 million from $57.88 million. The company reported a net income of $1.02 million, a significant recovery from a loss of $51.46 million last year. Key segments include Renovaro Biosciences and BioSymetrics, focusing on advanced therapies and AI-driven solutions. Future plans involve developing new diagnostic platforms and seeking additional funding to address operational challenges following the bankruptcy of a subsidiary." datetime: "2026-02-17T20:21:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276164384.md) - [en](https://longbridge.com/en/news/276164384.md) - [zh-HK](https://longbridge.com/zh-HK/news/276164384.md) --- # Lunai Bioworks Inc. SEC 10-Q Report Lunai Bioworks Inc., a pioneering company in the biotechnology and biomedical AI sectors, has released its latest Form 10-Q report, showcasing a notable improvement in financial performance and outlining key operational developments. The company, which operates through its segments Renovaro Biosciences and BioSymetrics, focuses on advanced cell and gene therapies as well as AI-driven biomarker discovery and precision medicine. This report highlights the company's financial recovery and strategic business initiatives. **Financial Highlights** **Total Operating Expenses**: $5.13 million, reflecting a significant decrease from the previous year's $57.88 million due to the absence of goodwill impairment charges. **Net Income (Loss)**: $1.02 million, a substantial improvement from the previous year's loss of $51.46 million, primarily due to gains from the bankruptcy of a subsidiary. **Basic and Diluted Income (Loss) Per Share**: $0.04, compared to a loss of $3.20 per share in the previous year, indicating improved profitability. **Net Cash Used in Operating Activities**: $2.42 million, showing a reduction in cash outflow compared to the previous year's $4.58 million, attributed to better management of working capital. **Business Highlights** **Segment Performance**: Lunai Bioworks Inc. operates through two main segments: Renovaro Biosciences and BioSymetrics. Renovaro focuses on developing advanced cell and gene therapies for cancer and infectious diseases, while BioSymetrics specializes in biomedical AI for biomarker discovery and precision medicine. **Geographical Performance**: The company operates primarily in the United States and Canada, with BioSymetrics based in Canada. The geographical distribution of operations reflects the company's focus on leveraging AI and biotechnology advancements in these regions. **New Product Launches**: Renovaro Biosciences is working on several innovative therapeutic platforms, including RENB-DC11 for solid tumors and RENB-DC20 for triple-negative breast cancer. These platforms aim to induce long-term remission in some of the deadliest cancers. **Future Outlook**: The company plans to focus on the development, validation, and commercialization of its AI-driven diagnostics and therapeutic platforms. Management is also seeking additional funding to support these initiatives and address the company's working capital needs. **Operational Challenges**: The bankruptcy of GediCube B.V., a subsidiary, led to its deconsolidation, impacting the company's operational structure. Additionally, the company is facing challenges related to its financial condition, which may affect its ability to continue operations without securing additional funding. SEC Filing: Lunai Bioworks Inc. \[ LNAI \] - 10-Q - Feb. 17, 2026 ### Related Stocks - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [RENB.US](https://longbridge.com/en/quote/RENB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [LNAI.US](https://longbridge.com/en/quote/LNAI.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) ## Related News & Research - [Medicare is about to change a drug program that held down the cost of premiums. Here's what to know.](https://longbridge.com/en/news/294391519.md) - [Biotech experts want FDA drug reviews based on science, not politics](https://longbridge.com/en/news/293453841.md) - [Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in US](https://longbridge.com/en/news/293415324.md) - [AI investors may pivot to hyperscalers from chipmakers, Morgan Stanley says](https://longbridge.com/en/news/291809937.md) - [Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 | ALGS Stock News](https://longbridge.com/en/news/287726278.md)